Clinical Trials Browser

Has results × Gynecologic × 30 days × Clear all

NCT01167712 2026-03-18

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 3 Active not recruiting

692 enrolled 11 charts

Brenner Tumor, Fallopian Tube Neoplasms

NCT02466971 2026-03-18

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

Phase 3 Active not recruiting

450 enrolled 11 charts

Uterine Cervical Neoplasms, Vaginal Neoplasms

NCT02595892 2026-03-18

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Active not recruiting

70 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02839707 2026-03-18

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2/3 Active not recruiting

444 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03348631 2026-03-18

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Phase 2 Active not recruiting

62 enrolled 14 charts

Ovarian Neoplasms

NCT04034927 2026-03-18

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Phase 2 Active not recruiting

61 enrolled 15 charts

Fallopian Tube Neoplasms

NCT04539327 2026-03-18

Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study

51 enrolled 28 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03914612 2026-03-17

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Phase 3 Active not recruiting

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Phase 1 Completed

62 enrolled 17 charts

DermatologicGastrointestinalGenitourinaryGynecologic

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT04300647 2026-03-12

SKYSCRAPER-04

Phase 2 Completed

172 enrolled 27 charts

Uterine Cervical Neoplasms

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Phase 3 Active not recruiting

733 enrolled 21 charts 2 FDA

Ovarian Neoplasms

NCT03367247 2026-03-10

BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal

Phase NA Completed

121 enrolled 16 charts

GastrointestinalGynecologic

Ascites, Gastrointestinal Neoplasms, Ovarian Neoplasms

NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Phase 1/2 Completed

224 enrolled 15 charts

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

215 enrolled 30 charts

BreastGastrointestinalGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

Phase 3 Active not recruiting

643 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01116648 2026-03-05

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Phase 1/2 Active not recruiting

155 enrolled 34 charts

BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

NCT02345265 2026-03-05

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Phase 2 Active not recruiting

70 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Active not recruiting

579 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02502266 2026-03-05

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Phase 2/3 Active not recruiting

582 enrolled 21 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04697628 2026-02-24

innovaTV 301

Phase 3 Completed

502 enrolled 18 charts 1 FDA

Uterine Cervical Neoplasms

NCT03617679 2026-02-23

Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

Phase 2 Active not recruiting

79 enrolled 12 charts

Endometrial Neoplasms

NCT04221945 2026-02-20

KEYNOTE-A18

Phase 3 Completed

1,060 enrolled 30 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms